✨
AI Summary
- Focus on Akeso's enavatuzumab potentially changing first-line lung cancer treatment.
- Discussion on whether PD-(L)1/VEGF bispecific antibodies will face off in China.
- Potential for head-to-head Phase III trials in China was explored.